Associations were sought between major histocompatibility complex (MHC) genes on chromosome 6 and the complement component C3 and immunoglobulin genes located on other chromosomes which might contribute to susceptibility to mild inflammatory arthritis (IA) or definite rheumatoid arthritis (RA). Frequencies of the complement C3F allele were raised in patients with IA but were normal in patients with RA and controls. When associations between C3F and MHC genes were sought frequencies of some MHC genes were greater in patients with C3F than in those without-for example, HLA-B8 and DR3 in patients with RA and DR2 in patients with IA. Conversely, DR4 frequency was lower in patients with IA with C3F than in those without. Thus the C3F allele may act independently or exert an epistatic effect on MHC genes to increase susceptibility or protect against disease.
Abstract
Associations were sought between major histocompatibility complex (MHC) genes on chromosome 6 and the complement component C3 and immunoglobulin genes located on other chromosomes which might contribute to susceptibility to mild inflammatory arthritis (IA) or definite rheumatoid arthritis (RA) . Frequencies of the complement C3F allele were raised in patients with IA but were normal in patients with RA and controls. When associations between C3F and MHC genes were sought frequencies of some MHC genes were greater in patients with C3F than in those without-for example, HLA-B8 and DR3 in patients with RA and DR2 in patients with IA. Conversely, DR4 frequency was lower in patients with IA with C3F than in those without. Thus the C3F allele may act independently or exert an epistatic effect on MHC genes to increase susceptibility or protect against disease.
The frequency ofthe immunoglobulin heavy chain aliotype Glm(2) on chromosome 14 was increased in patients with RA but only in those with the phenotype Gml,2,3,17;21,5; no significant associations were found between MHC genes and Gm phenotypes. Further, no associations of MHC, C3F, and immunoglobulin genes were shared by patients with RA and those with UA, indicating a different genetic basis for the two clinical entities.
In this paper we have compared the frequencies of C3 and Gm alleles in patients with RA and IA and sought interactions of these alleles with the MHC genes associated with RA. Our aim was to discover if other genes as well as those in the MHC might (a) predispose to RA, (b) predispose to mild inflammatory arthritis, or (c) protect patients with IA from developing definite RA. In patients with RA we found some associations between the C3F allele of the complement component C3 and MHC genes; an association was also found between RA and the Gm allotype Glm(2). The C3F allele may also be relevant in patients with IA, particularly when associated with HLA-B62, DR4, or DR2.
Patients and methods

PATIENTS
The 61 patients with RA who were typed for MHC antigens, complement component C3, and Gm allotypes are described in the accompanying paper.' Thirty five additional patients with definite or classical RA23 were included in the study on Gm allotype frequencies; no MHC or complement allotypes were determined in these patients.
Similarly, 49 patients with IA typed for MHC, C3, and Gm allotypes, are also described in the accompanying paper.' Fifty six additional patients with IA were Gm allotyped; three of these were also typed for MHC and C3 allotypes. 14) . 12 The C3F gene frequencies in our patients with RA and controls were also within this range but the frequency in our patients with IA was higher. Discrepancies between the various studies might be explained by clinical ascertainment of RA because Bronnestam, for example, included 'probable' RA and a high proportion (38%) of patients seronegative for rheumatoid factor. Bronnestam found that the C3F gene frequency was highest in patients without RA with the highest titres of rheumatoid factor but that the frequency in seropositive patients without RA was lower than that in controls; he therefore concluded that the C3F gene was associated with a clinical diagnosis of RA but not with the occurrence of rheumatoid factor. In our study a distinction was drawn between patients with RA (definite or classical), of whom 81% were seropositive, and patients with IA, who included those classified as 'possible' or 'probable' RA, of whom 92% were seronegative. Thus we suggest that the C3F gene is more likely to be a marker for mild self-limiting seronegative arthritis than for seropositive definite RA.
The associations found between HLA genes and C3F in patients with RA and those with IA are more difficult to interpret. Thomson et al compared the frequencies of C3 genetic variants in DR4 positive and DR4 negative patients but detected no associations of C3 with DR4 in RA.'2 A similar analysis of our patients also showed no associations, partly because too few of our patients with RA (12) were DR4 negative. The converse method of analysis-namely, comparison of the frequency of DR4 genes in C3F positive and G3F negative patients with RA-also failed to show an association between G3F and DR4. Further analysis of HLA gene frequencies in C3F positive and negative patients, however, showed several distinctive features. Firstly, HLA-B8 and DR3, which are in linkage disequilibrium and are associated with other autoimmune diseases, were not raised overall in patients with RA but were associated with C3F positive patients with RA. Secondly, DR2, which was low in our patients with RA and is considered to be protective in RA,4 was associated with IA in C3F positive patients. Thirdly, some gene frequencies-notably, B40, B62, and DR4-which were high in C3F positive patients with RA were unexpectedly low in C3F positive patients with IA; this suggests an inverse relation between RA and IA in their association of C3F with HLA genes and emphasises the genetic differences already reported between patients with RA and those with IA.1 All three HLA genes are implicated in RA in their own right, irrespective of C3,'5 therefore C3F may have an independent role in conferring susceptibility or protection in both clinical situations.
The significantly increased frequencies of both Glm(2) and the Gm phenotype Gml,2,3,17;21,5 in patients with RA confirmed our preliminary study.8 Many, but not all, studies have reported associations of Glm(2) with RA and in three of these Glm(2) was associated with DR4 positive RA (summarised in ref 16) . In these reports, however, frequencies of Gm phenotypes containing Glm(2) and their importance in RA vary considerably. Indeed one study on 
